GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

MRT-6160   Click here for help

GtoPdb Ligand ID: 14337

Synonyms: compound 161 [WO2024151547A1] | MRT6160
Compound class: Synthetic organic
Comment: MRT-6160 is a cereblon-based molecular glue degrader. It is designed to target the Rho-family guanine nucleotide exchange factor (GEF) and adaptor protein VAV1 as a neosubstrate [3]. VAV1 is a key signaling protein downstream of both the T- and B-cell receptors that is proposed as a novel target for immunomodulator development for the treatment of hematological malignancies and autoimmune diseases [1-2,4]. Selective degradation is proposed to disrupt the GEF and scaffolding activities of VAV1.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 66.48
Molecular weight 392.84
XLogP 0.88
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1=CC(=O)N(C=C1)C2=CC=C(C=C2)C3=C(C(=CC=C3)C4CCC(=O)NC4=O)Cl
Isomeric SMILES C1CC(=O)NC(=O)C1C2=CC=CC(=C2Cl)C3=CC=C(C=C3)N4C=CC=CC4=O
InChI InChI=1S/C22H17ClN2O3/c23-21-16(4-3-5-17(21)18-11-12-19(26)24-22(18)28)14-7-9-15(10-8-14)25-13-2-1-6-20(25)27/h1-10,13,18H,11-12H2,(H,24,26,28)
InChI Key RIFDPWJLHNZGEX-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
A first-in-human study of MRT-6160 in healthy subjects has been completed.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06597799 First-in-human Study of MRT-6160 in Healthy Subjects Phase 1 Interventional Monte Rosa Therapeutics, Inc